Nonconventional Products & Drugs in MTPs: Blood Banker vs Clinician (21EL-622)

Please note: AABB reserves the right to make updates to this program.

• Educational Track: Technical/Clinical
• Topics: Complications, Outcomes, Patient Blood Management, Patient Transfusion, Therapeutic Goals, Transfusion Process, Transfusion Safety
• Intended Audience: Hospital Blood Banks, Hospitals, Laboratory Staff, Medical Directors, Nurses, Physicians, Residents/Fellows, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
• Teaching Level: Advanced, Intermediate

• Director/Moderator: Amit Gokhale, MD, Transfusion Medicine & Coagulation Physician, Texas Children's Hospital, Assistant Professor of Pathology & Immunology, Baylor College of Medicine, Houston, TX
  Speakers:

  • Christopher Tormey, MD, Director, Transfusion Medicine Service, Yale New Haven Hospital, Director, Transfusion Medicine Fellowship, Professor of Laboratory Medicine, Yale School of Medicine, New Haven, CT
  • Martin A. Schreiber, MD, FACS, FCCM, Professor of Surgery, Division of Trauma, Critical Care and Acute Care Surgery, Oregon Health & Science University, Portland, OR

• Program Description

  Hemorrhage remains a major cause of potentially preventable morbidity and mortality in patients. Massive blood loss is encountered in various clinical situations such as trauma, major surgery, gastrointestinal bleeds, and obstetrical hemorrhage. Massive transfusion protocols (MTPs) are activated by clinicians in response to massive bleeding. MTPs have a predefined ratio of red blood cells, plasma, and platelet units in each pack for transfusion. These protocols ensure rapid and timely delivery of blood products to facilitate resuscitation. Along with conventional blood products, other blood products and pharmaceutical agents can also be of benefit. Drugs such as tranexamic acid have been shown to significantly reduce mortality in trauma patients and have been found to be beneficial in reducing bleeding in cardiac surgeries. There has also been a shift in greater use of whole blood as it has been shown that blood component therapy does not contain the same levels of platelets, coagulation factors and fibrinogen found in whole blood. This eCast will further explore the use of these and other non-conventional blood products in the setting of massive transfusion. This program will be presented though the lens of the laboratory personnel (blood banker) vs the clinician (trauma surgeon).

  Learning Objectives

  After participating in this educational activity, participants should be able to:

  • Define massive blood transfusion and massive transfusion protocol.
  • Identify the non-conventional blood products and pharmaceutical agents that can be potentially used during a massive transfusion.
  • Describe benefits and limitations of these nonconventional products vs conventional blood products.

  Registration

  Registration includes access to both the live and on-demand version of this eCast.

  AABB understands the value of learning together as a group but with COVID-19, bringing everyone together to share the experience in person may not be an option for your team. Given this, all participants in a group will be provided the ability to register as a single viewer (AABB will provide a promocode to registered group viewing coordinators to share with their team in advance of the live program). If you are a facility interested in participating in this eCast, simply complete the Group Viewing registration form and AABB will provide detailed instructions to share with your team. For single viewers, the process has not changed – simply click on the Register button below to register.

  Please note: registration for the live eCast will close 1 hour prior to the eCast start time. If you register after this time you will receive access to the on-demand eCast when it is available.

  Single Viewer	Register
  Group Viewing	Register

  Continuing Education Credit

  AABB estimates both the live and on-demand version of this eCast each to be eligible for 1 continuing education credits/contact hours for Physicians, California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The final number of credit(s) and credit types awarded for this program (live or on-demand) will be determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.

  Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.

  Speaker Biographies

  Dr. Christopher Tormey is a pathologist (board certified in Clinical Pathology as well as Blood Banking/Transfusion Medicine) in the Department of Laboratory Medicine at Yale University. Clinically, Chris is the Medical Director of the Transfusion Service at Yale-New Haven Hospital (New Haven, CT) and also providing Clinical Pathology and Laboratory Hematology services at Yale-New Haven Hospital. From the research standpoint, Chris has several investigative interests including: alloimmunization to non-ABO antigens in the setting of transfusion or pregnancy; examining the platelet storage lesion; and optimizing test performance/interpretation in hemostasis assays. In addition to the above, Chris is also the Director of the Transfusion Medicine fellowship at Yale and teaches medical/PA/nursing students, residents, and fellows at the Yale School of Medicine.

  Dr. Martin Schreiber’s special areas of interest are trauma surgery and surgical critical care. He received his medical degree in 1988 from Case Western Reserve University in Cleveland, OH. Dr. Schreiber completed his internship at Madigan Army Medical Center in Fort Lewis, WA., and his residency training at the University of Washington in Seattle. His trauma and critical care fellowship was completed at the University of Washington.